List of Excipients in Branded Drug RALOXIFENE HYDROCHLORIDE

Generic Drugs Containing RALOXIFENE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	raloxifene hydrochloride	0093-7290	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	raloxifene hydrochloride	0093-7290	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	raloxifene hydrochloride	0093-7290	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in RALOXIFENE HYDROCHLORIDE?

# Of NDCs	Excipient
9	ANHYDROUS LACTOSE
23	CELLULOSE, MICROCRYSTALLINE
12	CITRIC ACID MONOHYDRATE

Raloxifene Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Raloxifene hydrochloride is a low-solubility, extensively metabolized selective estrogen receptor modulator supplied primarily as a 60 mg immediate-release tablet. The originator product, Evista, has lost market exclusivity, and generic raloxifene is widely available. Commercial opportunity therefore depends on differentiated delivery, improved tolerability, patient adherence, or a new regulatory pathway rather than simple replication of the reference tablet.

The strongest excipient strategies target dissolution, absorption variability, tablet performance, and lifecycle extension. Potential platforms include amorphous solid dispersions, nanosized drug systems, lipid-based formulations, cyclodextrin complexes, and patient-friendly dosage forms. The most defensible commercial products would combine a measurable pharmacokinetic or adherence benefit with a patentable composition or manufacturing process.

What is raloxifene hydrochloride used for?

Raloxifene hydrochloride is approved for postmenopausal osteoporosis and for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or elevated breast cancer risk. It is not approved for treating established breast cancer or preventing cardiovascular disease.

Attribute	Raloxifene hydrochloride
Active ingredient	Raloxifene hydrochloride
Drug class	Selective estrogen receptor modulator
Main brand	Evista
Common strength	60 mg tablet
FDA approval	Evista approved in 1997
Main dosage form	Oral immediate-release tablet
Bioavailability	Approximately 2%, primarily because of extensive first-pass metabolism
Key pharmacokinetic issue	Low and variable systemic exposure
Generic status	Generic products are commercially available in the United States
Principal safety concern	Venous thromboembolic events
Other relevant adverse effects	Hot flashes, leg cramps, peripheral edema

Raloxifene has estrogen-agonist effects in bone and estrogen-antagonist effects in breast tissue. Its limited use in menopausal symptom management restricts some commercial opportunities that apply to other estrogen-related products. The approved indication set also means that any new formulation claiming improved osteoporosis or breast-cancer-risk outcomes will require careful clinical and regulatory planning. [1]

What excipients are used in Evista and generic raloxifene tablets?

The Evista label identifies conventional oral-tablet excipients, including lactose, povidone, crospovidone, magnesium stearate, polysorbate 80, and titanium dioxide. Exact excipient composition can differ among generic manufacturers and dosage forms. The reference product uses a conventional immediate-release film-coated tablet rather than a modified-release or specialized absorption-enhancing system. [1]

Functional role of the principal excipients

Excipient category	Typical function in raloxifene tablets	Commercial relevance
Lactose	Diluent and compression aid	May create opportunities for lactose-free or low-lactose versions
Povidone	Binder and wetting aid	Supports granulation and tablet strength
Crospovidone	Superdisintegrant	Helps offset poor API dissolution
Polysorbate 80	Surfactant and wetting agent	Improves wetting of poorly soluble raloxifene
Magnesium stearate	Lubricant	Excess use can slow wetting and dissolution
Titanium dioxide	Opacifier and colorant	Relevant to film-coat differentiation and excipient restrictions
Film-coat polymers	Tablet protection, appearance, swallowability	Can support taste, handling, and branding strategies

Raloxifene hydrochloride is generally described as practically insoluble in water. Its low oral bioavailability reflects both dissolution limitations and extensive hepatic first-pass metabolism. Increasing dissolution alone may not produce a proportional increase in exposure, so formulation development must evaluate solubility, permeability, metabolism, and food effects together. [1,2]

Which excipient strategies can improve raloxifene bioavailability?

The most relevant strategies are those that increase the amount of dissolved raloxifene at the intestinal absorption site while maintaining dose uniformity and chemical stability.

Amorphous solid dispersions

An amorphous solid dispersion can reduce the crystallinity-associated dissolution barrier by distributing raloxifene within a polymeric matrix. Candidate polymers include hypromellose acetate succinate, hypromellose, povidone, copovidone, and polyvinyl caprolactam-based systems.

Key development issues include:

• Maintaining supersaturation after dissolution
• Preventing raloxifene recrystallization
• Controlling residual solvent
• Managing hygroscopicity
• Demonstrating physical stability during accelerated storage
• Establishing a scalable spray-drying or hot-melt-extrusion process

A solid dispersion is commercially attractive because it can support both composition and process patent claims. The formulation must demonstrate a clinically meaningful benefit, since a laboratory dissolution improvement may not overcome raloxifene’s first-pass metabolism.

Nanocrystals and nanosuspensions

Nanocrystal technology can increase surface area and dissolution rate without requiring a large excipient load. Stabilizers such as poloxamers, polysorbates, hydroxypropyl cellulose, or povidone may be used to prevent aggregation.

A nanocrystal tablet could preserve the convenience of a once-daily solid dosage form. The main risks are particle-size control, long-term aggregation, scale-up, and the need to establish bioequivalence or clinical bridging. Claims covering particle-size distribution, stabilizer ratios, and redispersion characteristics may provide stronger protection than a generic statement that the formulation contains nanoparticles.

Lipid-based formulations

Self-emulsifying drug delivery systems and supersaturating lipid systems can improve apparent solubility and intestinal presentation. Potential excipient classes include medium-chain triglycerides, long-chain glycerides, oleic acid derivatives, polyethylene glycol-based surfactants, and precipitation inhibitors.

This approach may be useful where raloxifene exposure is limited by dissolution and intestinal solubilization. It introduces practical challenges:

• Tablet or capsule fill-volume constraints
• Softgel or liquid-filled capsule manufacturing
• Excipient oxidation
• Drug precipitation after dilution
• Food-effect changes
• Packaging compatibility

A lipid formulation has greater differentiation potential than a conventional tablet but may require a more complex regulatory package.

Cyclodextrin complexes

Hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-beta-cyclodextrin can improve apparent aqueous solubility. These systems are more practical for liquid, sachet, or reconstitutable products than for a standard 60 mg compressed tablet because complexation may require substantial excipient quantities.

The commercial case is strongest for a liquid or dispersible formulation aimed at patients with swallowing difficulty. Dose-volume, cost, and taste remain constraints.

Surfactant and wetting systems

A lower-risk approach is to optimize surfactant type and concentration, granulation conditions, disintegrant level, and lubricant exposure. Polysorbate 80 is already associated with the reference product, so a new product relying only on routine wetting optimization may have weak patent differentiation.

The strategy becomes more defensible when linked to a defined particle-size distribution, co-processed excipient, porous carrier, or controlled granulation process.

What formulations are protected by raloxifene patents?

The original raloxifene compound and Evista product rights are no longer the primary commercial barrier to generic entry. Current opportunity lies in secondary patents covering formulation, dosage form, manufacturing, combination therapy, or a new therapeutic use.

Potential claim categories include:

1. Raloxifene solid dispersions with specified polymer ratios.
2. Nanocrystal formulations with defined particle-size limits.
3. Lipid-based systems with precipitation-inhibiting excipients.
4. Oral films, orally disintegrating tablets, or sprinkle products.
5. Taste-masked pediatric or geriatric formulations.
6. Low-dose or intermittent dosing regimens.
7. Combination products for osteoporosis or breast-cancer-risk reduction.
8. Manufacturing processes that produce a specific polymorph or amorphous profile.
9. Stability packages that protect the API from humidity or oxidative degradation.
10. Device or packaging systems that improve adherence.

A formulation patent must distinguish the product from the conventional raloxifene tablet through measurable technical features. Broad claims that merely list common excipients are vulnerable to enablement, written-description, obviousness, and inherency challenges.

When does raloxifene lose exclusivity?

Raloxifene’s practical U.S. exclusivity period has ended. Evista was approved in 1997, and generic raloxifene hydrochloride products are marketed. The reference product therefore does not provide a viable basis for a new entrant to obtain ordinary small-molecule market exclusivity through an ANDA.

Exclusivity issue	Commercial position
New chemical entity exclusivity	Expired
Reference-product market exclusivity	Expired
Original compound protection	Expired or commercially exhausted
Generic entry	Established
Current value of secondary patents	Depends on claim scope and remaining term
New-product exclusivity	Potentially available through a qualifying reformulation or new indication

A new formulation could pursue a 505(b)(2) application if it relies partly on FDA findings for raloxifene while introducing a formulation, dosing, or clinical-use difference that requires new information. A standard ANDA is more appropriate for a product that matches the reference drug in dosage form, strength, route, and performance.

What is the Orange Book status of raloxifene?

The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information. Because generic raloxifene products are approved, the product is not dependent on active originator exclusivity for market access. Orange Book status should be reviewed at the product level because listed patents, withdrawal dates, and applicant-specific approvals can change.

For a conventional generic, the main pathway is an ANDA with a Paragraph I, II, III, or IV certification as applicable. For a new formulation, an applicant would typically assess whether the product fits an ANDA, 505(b)(2), or full new drug application pathway.

Paragraph IV risk is most relevant when an applicant challenges a still-listed patent. For a new raloxifene formulation, the commercial risk shifts toward third-party secondary patents covering specific excipient systems, particle engineering, dosage forms, or methods of use.

Which companies are challenging raloxifene patents?

Generic competition is already established, and the market includes multiple manufacturers of raloxifene hydrochloride tablets. The original patent challenge period is historical rather than an emerging exclusivity event. Current competitive diligence should focus on:

• FDA-approved generic applicants
• ANDA holders and authorized distributors
• 505(b)(2) developers
• Owners of formulation or combination patents
• Contract manufacturers with spray-drying, hot-melt extrusion, or nanocrystal capability

A new entrant should search the FDA Orange Book, Drugs@FDA, FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, and the USPTO Patent Center for current product-specific filings. [3,4]

How strong is the patent estate for raloxifene reformulations?

The base compound estate is weak as a barrier to entry because generic raloxifene is established. A reformulation estate can be moderately strong if it includes multiple layers of protection:

Protection layer	Relative value
Broad API patent	Low for new commercial planning because expired
Simple excipient substitution	Low
Defined solid dispersion composition	Moderate to high
Particle-size and process claims	Moderate
Clinically validated pharmacokinetic improvement	High
New dosage regimen	Moderate to high if clinically supported
Combination product	Moderate, depending on components
Manufacturing and control strategy	Moderate as a supplement to composition claims

The strongest portfolio would combine composition claims, process claims, product-by-process limitations where appropriate, and method-of-use claims tied to a clinically meaningful outcome. Patent term should be aligned with development timing because a late-filed formulation patent may have limited life after launch.

What generic launch risks exist for a new raloxifene product?

A new product faces four principal launch risks.

Bioequivalence risk

Raloxifene has low bioavailability and substantial metabolism. A formulation that raises exposure may not be therapeutically interchangeable with a conventional tablet. FDA may require comparative pharmacokinetic data, food-effect studies, dose proportionality work, or additional clinical evidence depending on the pathway.

Safety exposure risk

Increasing raloxifene exposure could increase adverse-event concerns, particularly venous thromboembolism. A bioavailability-enhancing system must demonstrate that the exposure range remains clinically acceptable.

Commercial substitution risk

A new product competing against inexpensive generics must offer a clear benefit: lower dose, fewer tablets, reduced variability, improved tolerability, easier swallowing, or access to a defined patient segment.

Payer and reimbursement risk

The osteoporosis market includes generic bisphosphonates, denosumab, anabolic agents, and other therapies. A premium raloxifene product will need evidence that its delivery benefit reduces treatment discontinuation, improves persistence, or addresses an unmet administration need.

How does raloxifene compare with competing osteoporosis drugs?

Raloxifene has a differentiated breast-cancer-risk reduction profile but a narrower osteoporosis role than several competing products.

Product class	Main commercial strength	Excipient opportunity for raloxifene
Oral bisphosphonates	Low cost and broad use	Improve swallowing and dosing convenience
Denosumab	Injectable, six-month dosing	Position oral raloxifene around patient preference and adherence
Teriparatide and abaloparatide	Bone-building activity	Target patients unsuitable for anabolic injections
Romosozumab	Potent injectable option	Compete only in selected lower-risk or prevention settings
Raloxifene	Bone benefit plus invasive breast-cancer-risk reduction	Improve exposure consistency and oral convenience

Raloxifene’s clearest differentiation is its dual positioning in bone health and breast-cancer-risk reduction. That positioning does not remove its thromboembolic safety limitations and does not make it a general substitute for all osteoporosis therapies. [5]

What licensing and partnering opportunities exist?

Licensing value is more likely to arise from enabling technology than from the raloxifene molecule itself. Attractive partners include:

• Drug-delivery companies with amorphous-dispersion platforms
• Nanocrystal developers
• Softgel manufacturers
• Contract development and manufacturing organizations
• Generic companies seeking differentiated 505(b)(2) products
• Women’s-health companies with established prescriber and payer access

A licensable package should include formulation data, dissolution profiles, pharmacokinetic evidence, stability results, manufacturing scalability, and a patent filing strategy. A platform that improves raloxifene exposure without increasing peak-related safety concerns has greater value than a formulation that only improves in vitro dissolution.

What geographic markets offer the best opportunity?

The United States offers the clearest regulatory pathway but also has intense generic price competition. Europe and other regulated markets may support differentiated products where reimbursement recognizes adherence or administration benefits, although national pricing controls can limit returns.

Emerging markets may offer volume opportunities for affordable generic tablets, but excipient innovation must remain cost-sensitive. Lactose-free, humidity-stable, and compact tablets may have greater practical value than high-cost nanotechnology in these markets.

Geographic patent protection should focus on jurisdictions where a differentiated formulation can obtain approval and reimbursement. Filing in every market is unlikely to be efficient unless manufacturing, licensing, or local competition supports the expense.

Key Takeaways

• Raloxifene hydrochloride is an established generic oral drug with no meaningful primary-product exclusivity remaining.
• The main technical problem is low and variable oral exposure caused by poor solubility and extensive first-pass metabolism.
• Amorphous solid dispersions, nanocrystals, lipid systems, and patient-friendly dosage forms offer the strongest excipient-led opportunities.
• A routine excipient substitution is unlikely to support a durable commercial position.
• The strongest patent estate would combine composition, process, particle-engineering, and clinically supported method-of-use claims.
• A 505(b)(2) strategy may be more suitable than an ANDA for a formulation that materially changes exposure, dosage form, or clinical use.
• Safety assessment is central because exposure enhancement may increase thromboembolic risk.
• Commercial success depends on a measurable adherence, tolerability, dosing, or breast-cancer-risk-reduction advantage over low-cost generics.

FAQs

Can raloxifene hydrochloride be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could target patients with dysphagia, but taste masking, dose loading, moisture protection, and rapid dispersion would require development work. The dosage form could support a secondary formulation patent if it has distinctive composition or performance characteristics.

Is lactose-free raloxifene commercially attractive?

Potentially. A lactose-free tablet could address excipient intolerance and support institutional or patient-specific procurement, but lactose removal alone is unlikely to justify a substantial price premium. The product would need additional differentiation, such as improved dissolution or swallowing performance.

Could a raloxifene nanosuspension qualify for FDA approval through 505(b)(2)?

Potentially. A nanosuspension that changes bioavailability, dosage form, or dosing requirements may fit the 505(b)(2) framework, subject to FDA’s assessment of the bridging data and the extent of reliance on the reference product.

Are biosimilar competitors relevant to raloxifene hydrochloride?

No. Raloxifene hydrochloride is a chemically synthesized small molecule, not a biologic. Competition proceeds through generic drug pathways such as ANDA approval rather than biosimilar approval.

What is the most commercially practical raloxifene excipient strategy?

A scalable solid-dispersion or particle-engineered tablet is likely more practical than a complex liquid or injectable system. The preferred strategy would improve dissolution while controlling exposure, preserve once-daily dosing, and use excipients with established oral safety and global regulatory acceptance.

References

1. U.S. Food and Drug Administration. (2018). Evista (raloxifene hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020815s027s028lbl.pdf

2. National Library of Medicine. (n.d.). Raloxifene hydrochloride: Drug information and pharmacology. DailyMed. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Preventive Services Task Force. (2019). Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA, 322(9), 857-867. https://doi.org/10.1001/jama.2019.11885